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Background. Circumsporozoite protein (CS) is the antigenic target for RTS,S, the most advanced malaria
vaccine to date. Heterologous prime-boost with the viral vectors simian adenovirus 63 (ChAd63)-modified vaccinia
virus Ankara (MVA) is the most potent inducer of T-cells in humans, demonstrating significant efficacy when ex-
pressing the preerythrocytic antigen insert multiple epitope–thrombospondin-related adhesion protein (ME-TRAP).
We hypothesized that ChAd63-MVA containing CS may result in a significant clinical protective efficacy.
Methods. We conducted an open-label, 2-site, partially randomized Plasmodium falciparum sporozoite
controlled human malaria infection (CHMI) study to compare the clinical efficacy of ChAd63-MVA CS with
ChAd63-MVA ME-TRAP.
Results. One of 15 vaccinees (7%) receiving ChAd63-MVA CS and 2 of 15 (13%) receiving ChAd63-MVA ME-
TRAP achieved sterile protection after CHMI. Three of 15 vaccinees (20%) receiving ChAd63-MVA CS and 5 of 15
(33%) receiving ChAd63-MVA ME-TRAP demonstrated a delay in time to treatment, compared with unvaccinated
controls. In quantitative polymerase chain reaction analyses, ChAd63-MVA CS was estimated to reduce the liver
parasite burden by 69%–79%, compared with 79%–84% for ChAd63-MVA ME-TRAP.
Conclusions. ChAd63-MVA CS does reduce the liver parasite burden, but ChAd63-MVA ME-TRAP remains the
most promising antigenic insert for a vectored liver-stage vaccine. Detailed analyses of parasite kinetics may allow detec-
tion of smaller but biologically important differences in vaccine efficacy that can influence future vaccine development.
Clinical Trials Registration. NCT01623557.
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The worldwide burden of P. falciparum malaria re-
mains a major public health concern [1], with approx-
imately 207 million cases and 627 000 deaths worldwide
in 2012 [2]. The preerythrocytic P. falciparum vaccine
RTS,S, formed from fusion of the circumsporozoite
protein (CS) to the surface-antigen of hepatitis B
virus, is the most advanced malaria vaccine in develop-
ment. However, it confers only limited, relatively short-
lived protection in African infants [3–5].Analysis of the
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immunological correlates of immunity induced by RTS,S sug-
gests that high levels of antibodies against CS on the sporozoite
correlate with protection, with a possible minor contribution
from low levels of induced CD4+ T cells [6–8].While these clin-
ical results are the most effective to date in a field setting, there
remains a need to improve on this limited clinical efficacy [9, 10],
either through modifications to RTS,S or by developing vaccine
strategies that combine numerous antigens or vaccine platforms.
Increasingly, data from animal models and vectored immuni-
zations demonstrate a correlation between CD8+ T cells and im-
munity to liver-stage parasites, even in the absence of antibodies
[11–17]. Clinical vaccine development had been hampered by
the limited ability of traditional subunit vaccine strategies,
namely adjuvanted protein constructs, to induce high enough
numbers of antigen-specific CD8+ T cells that may confer pro-
tection [18]. However, more recently, adenoviral-vectored
malaria vaccines administered in heterologous prime-boost
regimens with a modified vaccinia virus Ankara (MVA) boost
have been capable of inducing good humoral and T-cell
responses that include high levels of CD8+ T cells [17–21].
These CD8+ T-cell responses have been associated with clinical
efficacy [17]. Given concerns regarding the effect of preexisting
immunity on the immunological potency of human adenovi-
ruses, simian adenoviruses (ChAd) are being developed as alter-
native, potent vectors [22]. Indeed, prime-boost vaccination
with ChAd63 and MVA expressing the leading preerythrocytic
antigen, ME-TRAP, is clinically the most potent inducer of
CD8+ T cells in humans and the most effective malaria vaccine
besides RTS,S, demonstrating efficacy, defined as sterile protec-
tion or delay, in 8 of 14 malaria-naive volunteers (57%) follow-
ing sporozoite challenge [17].
Given that CS is expressed during both the sporozoite and
liver stages of P. falciparum infection and therefore is possibly
susceptible to both humoral and cell-mediated immunity at
both stages, we assess here the efficacy of ChAd63-MVA
expressing CS. If effective, this vaccine could then be combined
with ChAd63-MVA expressing ME-TRAP or RTS,S, to improve
clinical efficacy. Following a phase 1a study of ChAd63-MVACS
in malaria-naive volunteers, in which the regimen was shown to
be safe and immunogenic (de Barra et al, submitted), we per-
formed a study of controlled human infection with Plasmodium
sporozoites (also known as “controlled humanmalaria infection”
[CHMI]) [23], using the standard challenge model involving in-
fectious bites from 5 mosquitoes, to compare the efficacy of
ChAd63-MVA CS with that of ChAd63-MVA ME-TRAP.
METHODS
Participants
The study was conducted at the Centre for Clinical Vaccinology
and Tropical Medicine, University of Oxford (Oxford, United
Kingdom), and at the National Institute for Health Research
(NIHR) Wellcome Trust Clinical Research Facility, part of
the University of Southampton and University Hospital South-
ampton National Health Service (NHS) Foundation Trust
(Southampton, United Kingdom). The challenge procedure
was performed as previously described [24], using 5 infecti-
ous bites from P. falciparum strain 3D7–infected Anopheles
stephensi mosquitoes. This took place at the Alexander Fleming
Building, Imperial College (London, United Kingdom), and
mosquitoes were supplied by the Department of Entomology,
Walter Reed Army Institute of Research (WRAIR; Washington,
DC). Healthy, malaria-naive men and non-pregnant women
aged 18–45 years were invited to participate in the study. All
volunteers gave written informed consent prior to participation,
and the study was conducted according to the principles of the
Declaration of Helsinki and in accordance with good clinical
practice. There was no selection of volunteers on the basis of
preexisting neutralizing antibodies to the ChAd63 vector before
enrollment. The full list of inclusion and exclusion criteria is
given in the Supplementary Materials.
Ethical and Regulatory Approval
All necessary approvals for the study were granted by the United
Kingdom National Research Ethics Service, Committee South
Central–Oxford A (reference 12/SC/0037), and the United
Kingdom Medicines and Healthcare Products Regulatory
Agency (reference 21584/0293/001-0001). The study was addi-
tionally reviewed by the Western Institution Review Board
(Seattle, WA; reference 20120266) at the request of the PATH
Malaria Vaccine Initiative and was approved. The Genetically
Modified Organisms Safety Committee of the Oxford Universi-
ty Hospitals NHS Trust (reference GM462.11.65) authorized
recombinant vaccine use. The trial was registered with Clinical-
Trials.gov (referenceNCT01623557). The local safety committee
provided safety oversight, and good clinical practice compliance
was independently monitored by an external organization
(Appledown Clinical Research, Great Missenden, United
Kingdom).
ChAd63 and MVA Vaccines
Generation, manufacture, and quality control monitoring of the
recombinant ChAd63 and MVA vectors encoding ME-TRAP
and CS have been previously described [de Barra et al, submit-
ted; 25]. The antigen ME-TRAP contains a fusion protein of a
multi-epitope string (ME), followed by preerythrocytic throm-
bospondin-related adhesion protein (TRAP) from P. falciparum
strain T9/96 [17].
The poor immunogenicity of the standard full-length CS in-
sert (CSO) previously used in clinical trials by our group [26–
29] suggested that there may be an important difference in the
intrinsic immunogenicity of CSO, compared with that of the
ME-TRAP insert. For this study, we used information from
multiple sources [30–32] to design a novel CS antigen that
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omits the extreme C-terminus of the protein that encodes the
glycophosphatidylinositol anchor sequence and may down-
modulate CS immunogenicity [de Barra et al, submitted; 33].
Study Design
This was a Phase I/IIa open-label, vaccine and CHMI trial
(Figure 1). Volunteers chose whether to participate as vaccinees
(groups 1 and 2) or unvaccinated controls undergoing CHMI
alone (group 3). Vaccinees were randomly allocated to groups
1 or 2. All vaccinations were administered intramuscularly
into the deltoid, with the ChAd63 and MVA-vectored vaccines
administered in alternating arms. ChAd63-vectored vaccines
were administered on day 0, and MVA boost was administered
on day 56. Details of dosing, clinical follow-up and safety mon-
itoring are given in Supplementary Information. An interval of
1–14 days was allowed between vaccination and follow-up visits
after vaccination. CHMI was performed on day 77. Throughout
this article, “study day” refers to the nominal time point for a
group and not the actual day of sampling.
Ex Vivo Interferon γ (IFN-γ) Enzyme-Linked Immunosorbent Spot
(ELISPOT) Analysis
Ex vivo (18-hour stimulation) ELISPOT assays for ME-TRAP
and CS were performed on fresh (ie, not previously frozen) pe-
ripheral blood mononuclear cells (PBMCs) from blood samples
obtained on days 0, 14, 28, 56, and 63 after vaccination and on 1
day before and 7, 35, and 90 days after CHMI. Antigens were
tested in duplicate with 250 000 freshly isolated PBMCs added
to each well. Details about the ELISPOT methods are available
in the Supplementary Materials.
Total Immunoglobulin G (IgG) Enzyme-Linked Immunosorbent
Assay (ELISA)
Antibody responses were assessed using serum samples collect-
ed on days 0, 28, 56, and 63 after vaccination and 1 day before
and 35 and 90 days after CHMI. Antibody responses to TRAP
were measured by an IgG ELISA performed at the Jenner Insti-
tute (Oxford; Supplementary Materials). Antibody responses to
CS were measured by an IgG ELISA performed at the WRAIR
International Reference Center for Malaria Serology (Supple-
mentary Materials) [34].
Parasite Quantitative Polymerase Chain Reaction (qPCR)
qPCR for P. falciparum was conducted as described previously
[35] (see Supplementary Materials).
Criteria for Malaria Diagnosis
Diagnosis of malaria following CHMI was defined as positive
findings of thick filmmicroscopy, with at least 1morphologically
normal malaria trophozoite seen by ≥1 experienced microsco-
pist. qPCR was simultaneously performed, although investiga-
tors directly involved in clinical management were blinded to
these results. For volunteers with positive findings of thick
film microscopy but no symptoms consistent with P. falciparum
infection, investigators were unblinded to the qPCR results,
with the volunteer treated only if any preceding samples had
>500 parasites/mL. For volunteers with symptoms or signs
that, in the opinion of the clinical investigators, likely represent-
ed malaria (eg, fever, rigors, or severe symptomatology), despite
negative findings of thick film microscopy and no alternative
cause, investigators were unblinded to the qPCR results. If
any volunteer’s preceding samples had >500 parasites/mL, the
volunteer was treated for malaria. A vaccinee was classified as
a participant who demonstrated a delay to patency/treatment
if treatment was started >2 times the standard deviation in
days after the mean time to treatment of unvaccinated control
volunteers. This corresponds to clearance of an estimated >95%
of preerythrocytic-stage parasites [36].
Statistical Analysis
Data were analyzed using GraphPad Prism, version 5.03 for
Windows (GraphPad Software, La Jolla, California). Individual,
geometric mean (GM), or median responses for measurements
within each group are described. Parasite densities were log
transformed to remove skewness, with 1 added to each value
to allow transformation of zero values. Significance testing of
differences between groups used either a 2-tailed t test or the
2-tailed Mann–Whitney test (or the Kruskal–Wallis test, for
comparisons of >2 groups) for nonparametrically distributed
data. Correlations were assessed using the Spearman rank cor-
relation coefficient. Time to treatment was analyzed using
Kaplan–Meier survival curves, and between-group comparisons
were made using the log-rank test.
RESULTS
Recruitment and Vaccinations
Recruitment took place between March and June 2012. Thirty
healthy malaria-naive adult volunteers (10 women and 20 men)
were enrolled as vaccinees across 2 sites in the United Kingdom.
Six further volunteers (5 women and 1 man) were enrolled to
undergo CHMI as unvaccinated infectivity controls (Figure 1).
The mean age of volunteers was 26.4 years (range, 19–40 years).
Vaccinations began in April 2012, CHMI occurred in July 2012,
and all follow-up visits were completed by November 2012. All
vaccinees received their immunizations as scheduled. All doses of
vaccines were the same as those used in the comparable phase 1a
studies [de Barra et al, submitted; 25]. All volunteers underwent
CHMI 15–21 days after MVA immunization (ie, on days 71–77).
Vaccine Safety and Reactogenicity
No unexpected or serious adverse events (AEs) related to vacci-
nation occurred. The local and systemic (Supplementary
Figure 1) reactogenicity profile of each vaccine was similar to
phase 1a data [de Barra et al, submitted; 25].
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T-Cell Immunogenicity to ChAd63-MVA CS and ME-TRAP
T-cell responses followed the expected kinetics after ChAd63 re-
ceipt [de Barra et al, submitted; 17, 25, 35, 37, 38], with peak re-
sponses seen 28 days after ChAd63 receipt (group 1 [CS]: GM,
343 spot-forming cells (SFCs)/million PBMCs [95% CI, 191–
617]; group 2 [ME-TRAP]: GM, 553 SFCs/million PBMCs
[95% CI, 330–925]). The peak T-cell response after boost was
seen at day 63 after receipt of MVA CS for group 1 (GM,
1017 SFCs/million PBMCs [95% CI, 630–1641]) and at 1 day
before CHMI after MVA ME-TRAP receipt for group 2 (GM,
2027 SFCs/million PBMCs [95% CI, 1472–2792]; Figure 2A
and 2B). There was no significant difference in T-cell responses
between day 63 after vaccination and 1 day before CHMI for
either group.
Responses to both antigens were well maintained, with GMs
of 285 SFCs/million PBMCs (95% CI, 156–520) to CS and 659
Figure 1. Flow of study design and volunteer recruitment. Twenty volunteers were excluded following screening for the following reasons: psychiatric
history (n = 3), no medical screening letter returned (n = 3), multiple medical problems (n = 2), excessive alcohol use (n = 2), syncope (n = 1), connective tissue
disease (n = 1), iron deficiency (n = 1), raised alanine aminotransferase level (n = 1), poor venous access (n = 1), gastrointestinal problems under investigation
(n = 1), family history of heart disease (n = 1), lost to follow-up (n = 1), unavailable during challenge (n = 1), and history of recreational drug use (n = 1).
Furthermore, 7 volunteers withdrew consent after screening but before enrollment. All immunizations were administered intramuscularly with sequential
vaccines administered into the deltoid of alternating arms. No enrolled volunteers withdrew from the study and all volunteers completed study visits as
scheduled. Abbreviations: ChAd63, simian adenovirus 63; CS, circumsporozoite protein; ME-TRAP, multiple epitope–thrombospondin-related adhesion pro-
tein; MVA, modified vaccinia virus Ankara; pfu, plaque-forming units; vp, viral particles.
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Figure 2. Antigen-specific T-cell responses to vaccination measured by
interferon γ enzyme-linked immunosorbent spot assay. Kinetics of T-cell
responses after vaccination with ChAd63-MVA encoding either circum-
sporozoite protein (CS; group 1; A) or ME-TRAP (group 2; B). Each line
represents an individual volunteer. **P < .01 and ***P < .001, by the
Kruskal–Wallis test with the Dunn multiple comparison test. C, Median
T-cell frequencies for both antigens by group. Mean T-cell frequencies
at day 28 after vaccination were 304 and 673 spot-forming cells (SFCs)
after ChAd63-MVA CS or ME-TRAP receipt, respectively, and at day 63
peaked at 1378 and 2068 SFCs after ChAd63-MVA CS or ME-TRAP receipt,
respectively. Abbreviations: ChAd63, simian adenovirus 63; CHMI, con-
trolled human malaria infection; controls, unvaccinated volunteers
undergoing CHMI; ME-TRAP, multiple epitope–thrombospondin-related ad-
hesion protein; MVA, modified vaccinia virus Ankara; PBMC, peripheral
blood mononuclear cell.
Figure 3. Antibody responses to vaccination measured by enzyme-
linked immunosorbent assay (ELISA). A, Anti- circumsporozoite protein
(CS) immunoglobulin G (IgG) antibody responses after vaccination with
ChAd63-MVA CS (group 1; red) or ME-TRAP (group 2; blue). Lines represent
group medians. ***P = <.001 and *P = <.05, by the Friedman test compar-
ing responses before and after vaccination with the Dunn post hoc test. B,
Anti-TRAP IgG antibody responses after vaccination with ChAd63 ME-
TRAP (group 2). ***P = .0002, by the 2-tailed Wilcoxon matched pairs
test. C, Correlation between anti-CS IgG antibodies and CS-specific
T-cell immunogenicity the day before challenge in group 1. Spearman
r = 0.5; P = .08. Abbreviations: ChAd63, simian adenovirus 63; CHMI, con-
trolled human malaria infection; controls, unvaccinated volunteers under-
going CHMI; ELISPOT, enzyme-linked immunosorbent spot assay; EU,
ELISA units; ME-TRAP, multiple epitope–thrombospondin-related adhesion
protein; MVA, modified vaccinia virus Ankara; PBMC, peripheral blood
mononuclear cell; SFC, spot-forming cell.
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SFCs/million PBMCs (95% CI, 418–1036) to ME-TRAP 16
weeks after MVA receipt in groups 1 and 2, respectively (Fig-
ure 2C). T-cell responses among infectivity controls showed a
GM of 110 SFCs/million PBMCs (95% CI, 40–304) to CS and
a GM of 85 SFCs/million PBMCs (95% CI, 31–231) to ME-
TRAP 1 day before CHMI. These responses did not change sig-
nificantly during follow-up (Figure 2C).
Detailed mapping of T-cell responses to the ME-TRAP anti-
gen are outlined in the Supplementary Materials. Detailed
mapping of T-cell responses to CS peptides was not performed
because this was described recently in detail with several HLA
class I–restricted epitopes [39].
Antibody Immunogenicity of ChAd63-MVA CS and ME-TRAP
Anti-CS IgG antibody responses were measured in all vaccinees
(Figure 3A). Anti-CS IgG antibodies were detected in ME-
TRAP vaccinees (group 2) because of the inclusion of 4 copies
of the N-acetylneuraminic acid phosphatase (NANP) repeat
from the CS antigen in the ME string. In group 1, anti-CS
IgG responses peaked 21 days after MVA receipt, with a median
level of 2.1 µg/mL. In group 2, anti-CS IgG responses also peaked
21 days after MVA, but 8 of 14 volunteers in this group did not
have a measurable response, giving a median level of 0 µg/mL.
Anti-TRAP IgG antibody responses were assessed in group 2
only (Figure 3B) and also peaked 21 days after MVA ME-
TRAP receipt (median, 1475 ELISA units). A weak relationship
between anti-CS IgG antibody responses and CS-specific T-cell
responses 1 day before CHMI was observed in group 1 (r = 0.5;
P = .08, by 2-tailed Spearman correlation; Figure 3C). Exposure
to CHMI did not induce significant levels of anti-CS or TRAP
antibodies among infectivity controls (Figure 3A and 3B).
ChAd63-MVA Efficacy Among All Regimens Following
Sporozoite Challenge
The infectivity controls (group 3) and 27 of 30 vaccinees were di-
agnosed with malaria. One volunteer (7%) in group 1 (who re-
ceived ChAd63-MVA CS) and 2 volunteers (13%) in group 2
(who received ChAd63-MVA ME-TRAP) were sterilely protected
(Figure 4A). The control volunteers (group 3) were diagnosed after
a median time of 10.3 days, mean time of 10.5 days (range 8.0–
14.0, SD 2.2). Three vaccinees (20%) in group 1 and 5 vaccinees
(33%) in group 2 demonstrated a delay in time to treatment, rel-
ative to controls. There was no significant difference between un-
vaccinated controls and vaccinees in the protocol-specified end
point of time to treatment for malaria (Figure 4A). However,
when comparing the time to collection of the first sample after
CHMI with either >500 parasites/mL (Figure 4B) or >20 para-
sites/mL (Figure 4C), a significant difference was seen between
unvaccinated controls and vaccinees receiving ChAd63-MVA
ME-TRAP (P = .01 and P = .005, respectively).
qPCR Data
Primary analysis comparing the mean parasite density 7.5 days
after CHMI (a measure of the liver to blood inoculum) showed
a significant reduction when vaccinees receiving ChAd63-MVA
ME-TRAP but not ChAd63-MVA CS were compared with un-
vaccinated control volunteers (P = .01 and P = .08, respectively,
by the Mann–Whitney U test; Figure 5). The same comparison
performed using negative binomial regression gave P values of
.03 and .05, and a similar result was seen when the liver to blood
inoculum was estimated 7.5 days after CHMI by using simple
Figure 4. Efficacy of ChAd63-MVA circumsporozoite protein (CS) and
ME-TRAP immunization following Plasmodium falciparum 3D7 sporozoite
challenge. Kaplan–Meier survival analyses. Log-rank test for significance.
A, Kaplan–Meier survival analysis of time to treatment. Median time, 12.0
days for group 1 (CS), 12.5 days for group 2 (ME-TRAP), and 10.3 days for
unvaccinated controls. B, Kaplan–Meier survival analysis of time to first
sample with >500 parasites/mL detected by quantitative polymerase
chain reaction (qPCR). Median time, 10.5 days for group 1 (CS), 12.0
days for group 2 (ME-TRAP), and 7.5 days for unvaccinated controls.
C, Kaplan–Meier survival analysis of time to first sample with >20 para-
sites/mL detected by qPCR. Median time, 7.5 days for group 1 (CS),
9.0 days for group 2 (ME-TRAP), and 7.0 days for unvaccinated controls.
Abbreviations: CHMI, controlled human malaria infection; controls, un-
vaccinated volunteers undergoing CHMI; ME-TRAP, multiple epitope–
thrombospondin related adhesion protein.
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linear regression (P = .01 and P = .05, by the Mann–Whitney U
test).Mean total number of parasites 7.5 days after CHMI was a
strong predictor of the time to treatment (hazard ratio [HR],
1.003974 [95% CI, 1.002272–1.00568], by Cox proportional
hazards regression analysis; P≤ .0001).
Exploratory analysis of parasite densities by using area under
the curve (AUC) analysis showed that parasite density over the
first 3 replication cycles in infected volunteers was a significant
predictor of the time to treatment (HR, 1.000015 [95% CI,
1.000008–1.000022], by Cox proportional hazards regression
analysis; P < .000; Figure 6). Over the first, second, and third
blood-stage replication cycles, there was a significant reduction
in parasite densities among ChAd63-MVA ME-TRAP vacci-
nees, as measured by AUC analysis (ie, log [parasite density +
1]), compared with unvaccinated controls, when vaccinees who
achieved sterile protection were included in the analysis (cycle 1,
P = .01; cycle 2, P = .03; and cycle 3 P = .05; by the 2-tailed t test,
for all comparisons). Parasite densities in vaccinees receiving
ChAd63 CS were significantly less than those in controls over
the first blood-stage replication cycle only (P = .05 log [parasite
density + 1], by the 2-tailed t test). AUC analysis showed that,
compared with controls, ChAd63-MVA ME-TRAP resulted in
a 79% reduction in parasitemia during cycle 1, whereas
ChAd63-MVA CS caused a 69% reduction.
ChAd63-MVA Safety Among All Regimens Following Sporozoite
Challenge
No unexpected clinical or laboratory AEs were observed in vac-
cinees after CHMI, and there was no significant difference in
the number of AEs related to CHMI between groups (P = .72;
Supplementary Figure 3A). The total duration of symptoms in
volunteers with symptomatic malaria ranged from 1 to 19 days
(median, 6 days), with no significant difference between groups
(P = .33; Supplementary Figure 3B). There was no difference
between groups in the time that individuals were symptomatic
before treatment (P = .43; Supplementary Figure 3C) or the
number of symptoms present at time of treatment (P = .65) in
Figure 5. Comparison of mean parasite density, measured by quantita-
tive polymerase chain reaction, 7.5 days after controlled human malaria
infection (CHMI) between vaccinees and control volunteers. P values
were determined by the Mann–Whitney U test. Abbreviations: ChAd63,
simian adenovirus 63; Control, unvaccinated volunteers undergoing CHMI;
CS, circumsporozoite protein; group 1, ChAd63-MVA CS recipients; group 2,
ChAd63 ME-TRAP recipients; ME-TRAP, multiple epitope–thrombospondin-
related adhesion protein; MVA, modified vaccinia virus Ankara.
Figure 6. Comparison of areas under the curve (AUCs) of parasite den-
sities, measured by quantitative polymerase chain reaction (PCR), between
vaccinees and control volunteers. A, Group mean log-transformed PCR
data. The AUC of parasite density over the first 3 replication cycles in in-
fected volunteers was a significant predictor of the time to diagnosis (haz-
ard ratio, 1.000015 [95% confidence interval, 1.000008–1.000022], by Cox
proportional hazards regression analysis; P < .000). B, AUC analysis of par-
asite densities, comparing controls to vaccinees at days 6.5–8 (the first
cycle after hepatocyte release), days 8.5–10 (the second cycle), and days
10.5–12 (the third cycle) after controlled human malaria infection (CHMI).
Means of log [parasite density + 1] were compared for each vaccine group
to those of controls, using a 2-tailed t test. Abbreviations: ChAd63, simian
adenovirus 63; controls, unvaccinated volunteers undergoing CHMI; CS,
circumsporozoite protein; ME-TRAP, multiple epitope–thrombospondin-
related adhesion protein; MVA, modified vaccinia virus Ankara; SP, sterile
protection.
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volunteers with a diagnosis of malaria (Supplementary Fig-
ure 3D). Two of the 33 volunteers (6%) in whom malaria was
diagnosed after CHMI had no symptoms of malaria at diagno-
sis. Of the volunteers with a malaria diagnosis, 28 (85%) expe-
rienced at least 1 AE after challenge that was severe in intensity
(Supplementary Figure 3E). One volunteer in group 1 was ad-
mitted for inpatient management of vomiting secondary to an-
timalarial therapy (atovaquone/proguanil) 1 day after malaria
diagnosis and was discharged the next day with no sequelae.
Blood samples obtained 9, 35, and 90 days after CHMI and
within 24 hours of diagnosis demonstrated transient hemato-
logical and biochemical abnormalities at frequencies and sever-
ities expected following P. falciparum infection (Supplementary
Figure 3F) [40].
Associations Between Immunological Outcomes and Vaccine
Efficacy
In group 1 but not group 2, IgG antibody responses to CS cor-
related significantly and negatively with qPCR-determined den-
sities 7.5 days after CHMI (group 1: Spearman r = −0.6
[P = .03]; group 2: Spearman r =−0.3 [P = .34]; Figure 7A and
7B). A marginal negative correlation was seen in group 2 be-
tween IgG antibody responses to ME-TRAP and qPCR findings
7.5 days after CHMI (Spearman r = −0.5; P = .05; Figure 7C).
No significant correlation was seen between IFN-γ ELISPOT
findings for CS or ME-TRAP and qPCR findings 7.5 days
after CHMI for group 1 or 2 (Figure 7D and 7E ), in concor-
dance with previous data in which ELISPOT-determined
responses did not correlate with vaccine efficacy [17]. Pheno-
typing of the T-cell responses by flow cytometry was performed,
and results will be reported in a subsequent article.
DISCUSSION
In this first head-to-head comparison of the 2 leading preery-
throcytic antigens, ME-TRAP and CS, delivered in the same
vaccine platform, ME-TRAP had greater clinical efficacy, with
sterile protection achieved in 13% of vaccinees (2 of 15) and a
delayed time to diagnosis in 33% (5 of 15). This efficacy is
slightly less than that recently reported in another CHMI
study of ChAd63-MVA ME-TRAP [17], despite the induction
of similar, very high frequency of antigen-specific T cells
(peak median IFN-γ–secreting T cell count, 2027 in this
study vs 2436 SFCs/million PBMCs in the previous study). Be-
cause the median time to diagnosis for unvaccinated control
volunteers in this study was 1.5 days shorter than that of the
previously reported CHMI study [17], it is possible that a larger
challenge inoculum in this CHMI study could explain the small,
suggested difference in efficacy results (there were no other dif-
ferences in study methods). By the same reasoning, this could
mean that the efficacy attained with ChAd63-MVA CS (sterile
protection was achieved in 7% [1 of 15], and a delayed time
to diagnosis was achieved by 20% [3 of 15]) underestimates
that which may have been seen under less stringent CHMI
conditions. Indeed, given that the infectious dose experienced
by individuals in malaria-endemic countries is generally con-
siderably less than that administered in CHMI studies [23], ef-
ficacy may prove to be greater in field studies.
ChAd63-MVA CS induced moderate to high IFN-γ–
expressing T-cell responses, but anti-CS IgG levels were markedly
lower than that seen with in a sporozoite CHMI trial assessing
RTS,S, in which 50% of vaccinees (18 of 36) receiving RTS,S/
AS01B and 32% (14 of 44) receiving RTS,S/AS02A achieved ster-
ile protection (2.1 µg/mL with ChAd63 MVA CS vs 144 mg/mL
with RTS,S/AS01B and 83 mg/mL with RTS,S/AS02A) [41]. The
correlation between anti-CS antibodies and time to treatment
suggests this may, surprisingly, be contributing to the mechanism
of efficacy even at very low levels. This study provides the first ev-
idence that sterile immunity can be generated with viral vectors
encoding CS alone [41], although it is notable that some sterile
efficacy has been reported using combinations of DNA and ade-
noviral vectors encoding CS and AMA1 [18].
Kaplan–Meier analysis of time to diagnosis between vacci-
nees and unvaccinated controls and numerous analyses of the
qPCR data demonstrated significant efficacy for ChAd63-
MVA ME-TRAP alone. There was no such statistically signifi-
cant difference for the ChAd63-MVA CS vaccines using
the same analysis. However, the AUC analysis, comparison of
parasitemia at 7.5 days after CHMI, the evidence of sterile pro-
tection, and a delay to diagnosis in certain vaccinees all support
the view that ChAd63-MVA CS led to a reduction (by approx-
imately 69%–79%, depending on the analysis) in the number of
parasites released from the liver. Because ChAd63-MVA ME-
TRAP was, by use of the same measures, estimated to reduce
the liver parasite burden by 79%–84%, it appears that relatively
large reductions in liver-stage infection are required to signifi-
cantly influence clinical outcomes after mosquito bite CHMI, as
suggested previously [34, 35]. As this study shows, it can be diffi-
cult to quantify the efficacy of preerythrocytic vaccines that do not
provide sterile immunity. We would argue that, given the neces-
sarily small numbers of participants in CHMI studies and the im-
portance of CHMI studies to deselect novel vaccine strategies and
antigens [23], detailed analysis of qPCR data should be routinely
performed to ensure that promising signals suggestive of clinically
important efficacy are correctly identified.
Our data, importantly, compare the efficacy of ChAd63-
MVA containing CS or ME-TRAP and, together with previous
data comparing these antigens in DNA-MVA [25] and fowlpox-
MVA regimes [26, 27, 42], support ME-TRAP as currently the
most promising liver-stage antigen for inclusion in a future
multistage vaccine. However, given the efficacy we have demon-
strated here and the possibility that immunization with ME-
TRAP and CS could prove to be more efficacious than either
antigen alone, our next priority is to clinically assess the
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combination of ChAd63-MVA ME-TRAP and ChAd63-MVA
CS in a CHMI trial.
We suggest that detailed analyses of parasite kinetics should be
routinely performed in future CHMI vaccine studies to allow
detection of smaller but biologically important differences in vac-
cine efficacy that could influence future vaccine development.
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Figure 7. Associations between immunological outcomes and vaccine efficacy. Correlation between parasite density at day 7.5, measured by quanti-
tative polymerase chain reaction (qPCR), and levels of anti–circumsporozoite protein (CS) immunoglobulin G (IgG) antibody in group 1 (CS; Spearman
r =−0.6; P = .03; A) and group 2 (ME-TRAP; Spearman r =−.3; P = .34; B). C, Correlation between parasite density at day 7.5, measured by qPCR, and
anti-TRAP IgG antibody responses in group 2 (ME-TRAP; Spearman r =−0.5; P = .05). D, Correlation between interferon γ (IFN-γ)–secreting T-cell frequency
to CS measured by enzyme-linked immunosorbent spot (ELISPOT) parasite density at day 7.5 (parasite/mL measured by qPCR) in group 1 (CS; Spearman
r =−0.2; P = .50. E, Correlation between IFN-γ–secreting T-cell frequency to ME-TRAP measured by ELISPOT and parasite density at day 7.5 (parasite/mL
measured by qPCR) in group 2 (ME-TRAP; Spearman r = 0.1; P = .6). Abbreviations: Black filled points, sterilely protected vaccinees; EU, enzyme-linked
immunosorbent assay units; group 1, ChAd63-MVA CS; group 2, ChAd63-MVA ME-TRAP; ME-TRAP, multiple epitope–thrombospondin-related adhesion
protein; PBMC, peripheral blood mononuclear cell; SFC, spot-forming cell; unfilled points, vaccinees demonstrating delay to start of antimalarial therapy
in comparison to unvaccinated control volunteers.
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